Search
PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model
CEO Bharatt Chowrira and Co-Founder Eric Elenko describe the unmet need in IPF that exists today, and how their drug deupirfenidone was...
Dec 18, 2024
Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025
Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...
Dec 18, 2024
Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC
He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next...
Dec 16, 2024
Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology
He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...
Dec 16, 2024
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other...
Dec 16, 2024
BioVenture VoiCes Episode 8: Canaan Partners' Julie Grant
A general partner the firm, she describes her career path, including time spent at Goldman Sachs and Genentech, before landing at Canaan...
Dec 16, 2024
Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases
Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that...
Dec 13, 2024
Seattle and San Carlos, CA based Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work
He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use...
Dec 12, 2024
Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program
CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and...
Dec 12, 2024
Biotech CEO Sisterhood: Melinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles
Interviewed by Sisterhood editorial board member Grace Colón, Christine Miller describes taking the job at Melinta after a business...
Dec 12, 2024
Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed
He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral...
Dec 11, 2024
At an Innovation Day event hosted by Illumina in La Jolla, CA, BiotechTV got a look at the new MiSeq i100 series of benchtop sequencers
Product manager Emmanuel Naouri walks us through the new instrument and its features, including consumables that can be stored at room...
Dec 11, 2024
ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year
CMO Gianfranco Pittari describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has...
Dec 10, 2024
NewYorkBIO CEO Jennifer Hawks Bland discusses their annual event at the New York Stock Exchange and what is on the mind of companies today
Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE.
Dec 10, 2024
ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders
He discusses Nurix's clinical data set that was presented at ASH. Plus, the company's pipeline, including in the autoimmune space, and...
Dec 10, 2024
ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future
John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.
Dec 10, 2024
Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders
CEO Bruce Leuchter, a physician trained in neurology and psychiatry himself, describes the rational and structure behind Neurvati, and...
Dec 9, 2024
ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...
Dec 9, 2024
The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer
Jessica Ballinger describes the science behind this and how an extended release format can improve health outcomes. Plus, the progress...
Dec 9, 2024
ASH 2024: Kura Oncology CEO Troy Wilson highlights combination data in 1L AML for the menin inhibitor ziftomenib
He describes the data Kura has presented at ASH and where he believes it puts the company in the competive picture, including why 1L is...
Dec 9, 2024
.png){kind=logo}
